厄洛替尼及化疗同步配合放疗治疗晚期非小细胞肺癌临床观察  

Randomized clinical trail of three-dimension conformal radiotherapy combined with erlotinib or concurrent chemotherapy in treatment locally advanced non-small cell lung cancer

作　　者：岳养军[1] 李韵笙 李莎[1] 魏世华[1] 朱向辉[1] 田种泽[1] 

机构地区：[1]兰州军区兰州总医院放疗科,甘肃兰州730050 [2]兰州市肺科医院呼吸内科,甘肃兰州730046

出　　处：《中华肿瘤防治杂志》2011年第20期1628-1631,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:对比分析放射治疗同步联合厄洛替尼或化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法:治疗组17例,给予厄洛替尼150mg口服,1次/d。对照组18例,采用TP方案:顺铂30mg/m2,d1～d3;紫杉醇135mg/m2,d1。两组第1天同时开始放疗,总剂量60～70Gy/6～7周。结果:治疗组完全缓解率(CR)、部分缓解率(PR)、无变化+病变进展(SD+PD)分别为41.2%、52.9%和11.8%;对照组分别为38.9%、50.0%和11.1%,差异无统计学意义,χ2=0.004,P=0.952。1年生存率分别为76.4%、72.2%,差异无统计学意义,χ2=0.083,P=0.774。生活质量的改善稳定率分别为88.2%、72.2%,差异无统计学意义,χ2=1.401,P=0.237。血液(χ2=5.402,P=0.02)及上消化道反应(χ2=4.265,P=0.039)对照组高于治疗组,具有统计学意义。结论:放疗同步联合厄洛替尼联与同步联合化疗治疗NSCLC相比疗效相当,但毒性较低,安全性和耐受性比较好。OBJECTIVE ： To radiotherapy concurrent Erlotinib compare the curative effect of the or chemotherapy in advanced nonsmall cell lung cancer （NSCLC）. METHODS： Treatment group of 17 cases received erlotinib 150mg orally, d1. Control group of 18 cases received TP regimen chemotherapy;Cisplatin 30 mg/m2 ,d1- d3; paclitaxel 135 mg/m2 ,dl. Radiotherapy started in the first day of medication,with a total dose of 60-70 Gy in 6-7 weeks to complete. RESULTS： The rate of complete response （CR）, partial response （PR）, stable disease （SD）＋ progressive disease （PD） in treatment group were 41.2% ,52.9G and 11.8G respectively, and 38.9G, 50.0%, 11.1% respectively in control group, and the differences in two group had no statistical significance （x2 = 0. 004, P= 0. 952）. The survival rate of 1-year in treatment group was 76.4% ,and 72.2% in control group, the difference had no statistically significance （x2= 0. 083, P= 0. 774）. The rate of the life quality that improved and stabilized was 88.2 %, 72.2 %, and the difference had no statistically significance （x2=1. 401, P=0.237）. The blood system toxicity （x2=5.402,P= 0.02） and gastrointestinal reaction （x2 =4. 265 ,P=0. 039） side reactions of control group was higher than treatment group, and the difference has statistically significant. CONCLUSION： Compared with radiotherapy concurrent chemotherapy,Erlotinib combined with radiotherapy has equivalent curative effect, and has mild side reaction, good safety and tolerability.

关 键 词：癌 非小细胞肺/药物疗法 癌 非小细胞肺/放射疗法 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]